Moleculin Biotech, INC 10-Q quarterly reports

Moleculin Biotech reports significant net losses and negative stockholders' equity, raising substantial doubt about its ability to continue as a going concern, while advancing its lead drug Annamycin in Phase 3 trials.

Moleculin Biotech reported a widened net loss in Q2 2025, facing Nasdaq delisting concerns, while advancing its lead drug Annamycin into a pivotal Phase 3 trial with promising preclinical data and patent grants.

Moleculin Biotech's Q1 2025 report details financial results and provides updates on the clinical development of Annamycin, including progress on the Phase 3 MIRACLE trial.

Moleculin Biotech's Q3 2024 report highlights progress in Annamycin clinical trials and financial updates, including a recent equity raise.

Moleculin Biotech's Q2 2024 results show a net loss, but the company is progressing Annamycin to a Phase 3 trial for AML treatment.

Moleculin Biotech's Q1 2024 report shows a net loss but highlights positive clinical trial data for Annamycin and new patent issuances.